An international team of researchers led by Dr. Eleanor Fish, Scientist Emeritus at the Toronto General Hospital Research Institute, UHN, and professor in the University of Toronto‘s Department of Immunology, has shown for the first time that an antiviral drug can help speed up the recovery of COVID-19 patients.
According to the new study, published Friday in Frontiers in Immunology, treatment with interferon(IFN)- a2b may significantly accelerate virus clearance and reduce levels of inflammatory proteins in COVID-19 patients.
The research team found that treatment with this drug, which has been used clinically for many years, significantly reduced the duration of detectable virus in the upper respiratory tract, on average by about seven days. It also reduced blood levels of interleukin(IL)-6 and C-reactive protein (CRP), two inflammatory proteins found in COVID-19 patients.
Dr. Fish says the research team considered IFN-a therapy for COVID-19 after they demonstrated interferon provided therapeutic benefit during the SARS outbreak of 2002 and 2003.
“Rather than developing a virus-specific antiviral for each new virus outbreak, I would argue that we should consider interferons as the ‘first responders’ in terms of treatment,” says Dr. Fish.
“Interferons have been approved for clinical use for many years, so the strategy would be to ‘repurpose’ them for severe acute virus infections.”
Boosting a natural defence mechanism
Interferons are a group of signaling proteins released by the human body in response to all viruses. As Dr. Fish explains, they are a “first line of defence.”
They target different stages of a virus’s life cycle, inhibiting them from multiplying. They also boost an immune response by activating different immune cells to clear an infection. Some viruses, however, can block this natural defense mechanism.
“But it is possible to override this block. If a virus blocks interferon production, then treating with interferon can offset this.”
The researchers conducted this exploratory study on a group of 77 patients with COVID-19 in Wuhan, China. These patients were admitted to Union Hospital, Tongii Medical College, between January 16 and February 20, 2020. They represented moderate cases of the disease as none of the patients required intensive care or prolonged oxygen supplementation or intubation.
Despite the study’s limitations of a small, non-randomized group of patients, the work provides several important and novel insights into COVID-19 disease, notably that treatment with IFN-a2b can accelerate viral clearance from the upper respiratory tract and also reduce circulating levels of inflammatory factors that are associated with severe COVID-19.
Dr. Fish says a randomized clinical trial is a crucial next step. According to her, a clinical trial with a larger group of infected patients who are randomized to treatment or placebo would further this research.
In the meantime, the findings from this study are the first to suggest therapeutic efficacy of IFN-a2b as an available antiviral intervention for COVID-19, which may also benefit public health measures by shortening the duration of viral clearance and therefore slowing the tide of the pandemic.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Recovery of COVID-19 patients
- Denton County Reports 16 Deaths, 991 Cases of COVID-19 Monday; 4 ICU Bedson February 22, 2021 at 10:23 pm
Denton County Public Health reports 16 COVID-19 deaths and an additional 991 new cases of the virus Monday, their first report in more than a week after being delayed during last week’s winter storms.
- Can COVID-19 Cause a Heart Attack?on February 22, 2021 at 9:48 pm
You may think of COVID-19 as a disease that involves the lungs, since many people experience shortness of breath or trouble breathing, but a growing body of research shows that COVID-19 can attack the ...
- COVID-19 vaccine could affect eligibility to donate plasmaon February 22, 2021 at 7:58 pm
If you're 14 days past your COVID-19 diagnosis and 14 days symptom free, you're eligible to give convalescent plasma.
- Rheumatoid Arthritis Drug Shows Promise in Fighting Covid-19on February 22, 2021 at 4:50 pm
A new study shows an anti-inflammatory drug can help treat certain severe symptoms of Covid-19, and adds a tool for helping the sickest patients.
- Clinics are opening around the country to treat a potential 'second pandemic': Long COVID-19on February 22, 2021 at 1:30 pm
Some COVID-19 patients have had lingering symptoms for months. While most people with COVID-19 recover and return to normal health, some patients have gone on to have “long COVID,” experiencing ...
Go deeper with Google Headlines on:
Recovery of COVID-19 patients
Go deeper with Bing News on:
- Pan-serotype antiviral for dengue infectionon February 22, 2021 at 9:23 am
Dengue virus (DENV) is a mosquito-borne flavivirus that exists in four distinct serotypes and can cause severe disease and death. Antiviral drugs to specifically treat DENV infections are not ...
- Eswatini king recovers from COVID, thanks Taiwan for sending drugon February 20, 2021 at 6:40 am
King Mswati III says Taiwan President Tsai Ing-wen sent antiviral medication, which he didn’t name, to help him recover.
- These 3 existing drugs may fight against COVID-19on February 20, 2021 at 3:22 am
In a recent study at the University of Florida Health, researchers found that three common antihistamine medications could inhibit infection of cells by the COVID-19. The drugs, including hydroxyzine, ...
- eSwatini king says had COVID-19, recovered after Taiwan sent drugson February 19, 2021 at 10:35 pm
Swatini's King Mswati III said he had recovered from COVID-19 after Taiwan President Tsai Ing-wen sent antiviral medication to help him.
- Global Antiviral Drugs Market 2024 Segmentation by Types, Regions, Applications and Key Playerson February 19, 2021 at 9:48 pm
The global antiviral drugs market is expected to reach US$70.95 billion in 2024, increasing at a CAGR of 2.10%, for ...